PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Exp Immunol - 2 weeks (NewC3)
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Exp Immunol - 2 weeks - (New C3)
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
PD-L1 underexpression
|
LUAD
|
PD-L1 underexpression
|
LUAD
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
nivolumab Resistant: B - Late Trials
|
nivolumab Resistant: B - Late Trials
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
PD-L1 underexpression
|
Gastric Adenocarcinoma
|
PD-L1 underexpression
|
Gastric Adenocarcinoma
|
Immunotherapy Resistant: B - Late Trials
|
Immunotherapy Resistant: B - Late Trials
|
PD-L1 underexpression
|
Esophageal Adenocarcinoma
|
PD-L1 underexpression
|
Esophageal Adenocarcinoma
|
Immunotherapy Resistant: B - Late Trials
|
Immunotherapy Resistant: B - Late Trials
|
PD-L1 underexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 underexpression
|
Lung Non-Small Cell Squamous Cancer
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
camrelizumab Sensitive: C3 – Early Trials
|
camrelizumab Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
ipilimumab + cemiplimab Sensitive: C3 – Early Trials
|
ipilimumab + cemiplimab Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Urothelial Cancer
|
PD-L1 underexpression
|
Urothelial Cancer
|
nivolumab + IPI-549 Sensitive: C3 – Early Trials
|
nivolumab + IPI-549 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Mantle Cell Lymphoma
|
PD-L1 underexpression
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
PD-L1 underexpression
|
Cutaneous T-cell Lymphoma
|
PD-L1 underexpression
|
Cutaneous T-cell Lymphoma
|
durvalumab + lenalidomide Sensitive: C3 – Early Trials
|
durvalumab + lenalidomide Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Triple Negative Breast Cancer
|
PD-L1 underexpression
|
Triple Negative Breast Cancer
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
AML
|
PD-L1 underexpression
|
AML
|
XmAb14045 Sensitive: C3 – Early Trials
|
XmAb14045 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
|
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 underexpression
|
SCCHN
|
PD-L1 underexpression
|
SCCHN
|
cetuximab sarotalocan Sensitive: C3 – Early Trials
|
cetuximab sarotalocan Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
avelumab + VX15 Sensitive: C3 – Early Trials
|
avelumab + VX15 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Gastric Adenocarcinoma
|
PD-L1 underexpression
|
Gastric Adenocarcinoma
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 underexpression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
CRC
|
PD-L1 underexpression
|
CRC
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
|
durvalumab Resistant: C3 – Early Trials
|
PD-L1 underexpression
|
RCC
|
PD-L1 underexpression
|
RCC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
HCC
|
PD-L1 underexpression
|
HCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 underexpression
|
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
gemcitabine Sensitive: C3 – Early Trials
|
gemcitabine Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Triple Negative Breast Cancer
|
PD-L1 underexpression
|
Triple Negative Breast Cancer
|
carboplatin + paclitaxel Resistant: C3 – Early Trials
|
carboplatin + paclitaxel Resistant: C3 – Early Trials
|